REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions
REGENXBIO Inc. stock dropped Thursday, despite the company reporting that its experimental gene therapy for Duchenne muscular dystrophy hit the primary endpoint in a late-stage trial. Investors zeroed in on lingering safety issues and a murky regulatory path forward, eclipsing the positive trial result.
TechStock² Updates
![Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-0051-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]")
